8 recruiting, 1 not yet recruiting, 1 terminated. 10 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 8, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 8 | Recruiting 6, Not yet recruiting 1, Terminated 1 |
Follow Small Cell Lung Cancer ( SCLC ): new trials by email Literature Review of Small Cell Lung Cancer ( SCLC ) trials Research Report on Small Cell Lung Cancer ( SCLC )
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| A Study of Armored CAR T Cells in People With Cancer DLL3-SAVVYZ-IL18 CAR T cell - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-08-28 | 2026-10-22 |
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer | Phase 1 | Recruiting | Treeline Biosciences, Inc. | 120 | 2026-08-05 | 2026-10-01 |
| Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) IDP-121 - Small Cell Lung Cancer ( SCLC ) | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 60 | 2026-07-28 | 2026-10-07 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| Penfluridol for Relapsed/Refractory Small Cell Cancers Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer - Small Cell Carcinoma, Small Cell Carcinoma of Lung | Phase 1 / Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2025-10-01 | 2025-10-03 |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors CP-383 - Solid Tumor Malignancies, Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Tasca Therapeutics | 150 | 2025-08-27 | 2026-02-18 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) - Head and Neck Carcinoma, Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | VM Oncology, LLC | 242 | 2018-06-08 | 2025-12-11 |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer Carboplatin, Etoposide, MPDL3280A - Small Cell Lung Cancer ( SCLC ) | Phase 1 / Phase 2 | Terminated | Giuseppe Giaccone | 1 | 2016-03-01 | 2018-07-02 |
Small Cell Lung Carcinoma (10) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Carcinoma, Neuroendocrine (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Small Cell (1) · Disease (1) · Endometrial Neoplasms (1)
Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Lung Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Lung Neoplasms (7) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (3)
pembrolizumab (2) · Carboplatin (1) · Combined Modality Therapy (1) · Etoposide (1) · PM 01183 (1) · Penfluridol (1) · Tablets (1) · atezolizumab (1) · osimertinib (1) · venetoclax (1)
Giuseppe Giaccone (1) · IDP Discovery Pharma S.L. (1) · Memorial Sloan Kettering Cancer Center (1) · Misty Shields (1) · PMV Pharmaceuticals, Inc (1) · Peking University First Hospital (1) · Tasca Therapeutics (1) · Treeline Biosciences, Inc. (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · VM Oncology, LLC (1)
United States (6) · Australia (2) · China (2) · Spain (2) · France (1) · Germany (1) · Italy (1) · Puerto Rico (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Adam Schoenfeld, MD (1) · Marc Fellous, MD (1) · Misty D Shields, MD, PhD (1) · Padma Yerramilli-Rao, MB BS, PhD (1) · Peng Wu, PhD (1)
PMID 40543428, PMID 40932470, PMID 41740031
R01CA303470 (1)